ADDvise receives order from a subsidiary to BioGaia worth 2,1 MSEK

03-04-2017   Regulatory press release

ADDvise Group AB’s (publ) subsidiary LabRum AB has signed an agreement with BioGaia’s subsidiary TwoPac AB, for a delivery of laboratory furniture, safety ventilation products, such as fume cupboards and safety cabinets as well as certain laboratory equipment, such as refrigerators and freezers.

TwoPac AB is a company that develops and creates equipment for filling and packing of probiotic products. LabRum has helped TwoPac AB on site with projecting furniture, safety ventilation products and equipment. The order is worth approximately 2,1 MSEK and will be delivered during the second and third quarter of 2017.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on April 03, 2017 at 13:25 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com

Latest press releases

ADDvise acquires Seebreath AB

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

Interim report January 1 – March 31 2022

Regulatory

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…

ADDvise acquires Surplus Diabetics, Inc.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…